Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AqT-Doxorubicin
- Development stage
- Preclinical
- Lead developer
- AqueaTether Therapeutics
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
AqT-Doxorubicin is a specialized antibody-drug conjugate (ADC) payload developed by AqueaTether Therapeutics, a division of CellMosaic. It utilizes the proprietary AqueaTether (AqT) linker technology, which is a super-hydrophilic scaffold based on sugar alcohols. This technology is designed to improve the water solubility of the hydrophobic cytotoxic agent doxorubicin, allowing for high drug-to-antibody ratios (DAR) of 8 to 15 without causing antibody aggregation or instability. Doxorubicin, the active cytotoxic component, functions as a DNA-binding agent that intercalates into DNA, thereby interfering with replication and transcription processes. This platform asset is intended for use in the development of ADCs for the treatment of various cancers, providing enhanced biocompatibility and stability compared to traditional linker-payload systems.
- Other names
- DoxorubicinAqT-Doxorubicin (platform payload)
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on AqT-Doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AqT-Doxorubicin.